The objective of this study is to prepare biodegradable iron oxide nanoparticles with gelatin (GEL) for paclitaxel (PTX) delivery. In detail, Fe 3 O 4 nanoparticles were prepared and then coated them with GEL (Fe 3 O 4 @GEL) conjugate by co-precipitation method. Furthermore, the formation of Fe 3 O 4 @GEL was demonstrated by Fourier transform infrared (FT-IR) and powder X-ray diffraction (XRD). The superparamagnetic property of Fe 3 O 4 @GEL was also showed by hysteresis loop analysis, the saturation magnetization reached 20.36 emu.g -1 . In addition, size and morphology of Fe 3 O 4 @GEL nanoparticles were determined by transmission electron microscopy (TEM). The results indicated that Fe 3 O 4 @GEL nanoparticles were spherical shape with average diameter of 10 nm. Especially, PTX was effectively loaded into the coated magnetic nanoparticles, 86.7 ± 3.2 % for drug loading efficiency and slowly released up to 5 days. These results suggest that the potential applications of Fe 3 O 4 @GEL nanoparticles in the development of stable drug delivery systems for cancer therapy.
INTRODUCTION
Iron oxide nanoparticles (Fe 3 O 4 and γ-Fe 2 O 3 NPs), one of the most prominent properties of magnetic nanoparticles (MNPs), has been commonly used in biomedical applications such as in vivo magnetic resonance imagining, magnetic-mediated hyperthermia for cancer treatment and tissue-specific delivery of therapeutic agents [1, 2] . Moreover, if the size of magnetic structure is small enough MNPs may have superparamagnetic properties, becoming magnetized in the presence of a magnetic field and showing no magnetization in the absence of magnetic field [3, 4] . However, MNPs tend to aggregate and form a larger cluster because of magnetic dipoledipole attractions between NPs, which may limit their potential biomedical applications [5] . To overcome this drawback, MNPs were often surface modified with many materials such as silica, carbon, and biopolymers. These modifications are not only improving the chemical stability but also increase the biocompatibility of MNPs [6] .
Gelatin (GEL), a protein derived from collagen, possesses numerous useful features such as high solubility, biodegradability, biocompatibility and pH-induced surface charge. It can be widely used to bind with drug or poly(ethylene glycol) due to its multifunctional groups, like -NH 2 and -COOH [7, 8] . Furthermore, fibronections, are large glycoprotein found at cell surface, in extracellular matrices and in blood plasma, have binding sites for a number of other macromolecules, including GEL [9] . Moreover, tumor cell phagocytosis can be significantly enhanced in the presence of GEL [10] . There is some research using GEL-coated MNPs for delivery of chemo-and bio-therapeutic agents. Babita Gaihre and co-workers developed GEL A-and B-coated MNPs as potential nanocarriers for magnetic doxorubicin (DOX) targeting. The results demonstrated that electrostatic interactions between DOX and the coated MNPs played a crucial role in the encapsulation efficiency of the DOX, and pH-responsive drug release of DOX-loaded particles [11] . In addition, Erxi Che reported a magnetic targeted drug delivery system based on magnetic mesoporous silica NPs (MMSN), which were surface coated by GEL layer, for sustained release of paclitaxel (PTX). The results showed that the biodistribution of the GEL-coated MMSN were altered by external magnet, and therefore the higher concentration of these nanocarriers detected in tumor tissues than normal tissues. According to the result of tumor reduction study, the tumor growth of S180 tumor-bearing mice treated with the PTX-loaded carriers were significantly delayed without obvious body weight loss [12] . These results suggested that the GEL-coated MMSN can be used as promising drug carriers for effective delivery of anticancer drugs in the treatment of cancer.
In this study, we report the preparation and characterization of magnetite nanoparticles coated with GEL for PTX delivery system. GEL as polymeric outer layers were prepared and coated on Fe 3 O 4 NPs (Fe 3 O 4 @GEL NPs) which was prepared by the co-precipitation method. The obtained samples were then characterized by transmission electron microscopy (TEM), Fourier transform infrared spectra (FT-IR), powder X-ray diffraction (XRD), and vibration sample magnetometer (VSM). Especially, either drug loading efficiency or drug release behavior of PTX-loaded Fe 3 O 4 @GEL NPs were also evaluated. This study is expected to improve the stability of magnetic NPs for controlled delivery systems in cancer therapy.
MATERIALS AND METHODS

Materials
GEL type A was obtained from Sigma-Aldrich (St. Louis, MO, USA). Iron(III) chloride hexahydrate (FeCl 3 .6H 2 O, 97%), iron(II) chloride tetrahydrate (FeCl 2 .4H 2 O, 99%) and tetrahydrofuran (THF) were purchased from Merck (Germany). Ammonium Hydroxide (28-30%) was obtained from Tianjin Bodi Chemical Co., Ltd. (China). PTX was supplied by Samyang Corporation (Seoul, Korea). All chemicals and solvents were of highest analytical grade and used without further purification. 2) was added into the three-necked flask and constantly stirred under nitrogen. NH 4 OH solution (10 w/w%) was injected into the mixture and the reaction was maintained at room temperature under vigorously stirring for 1 h until pH reach to 10. The color of the solution changed to dark black. Thereafter, the precipitate was isolated by using a super magnet bar and rinsed with deionized water (deH 2 O) several times, sonicated and then freeze-dried to obtain Fe 3 O 4 NPs. 
Preparation of Fe 3 O 4 and Fe 3 O 4 @GEL MNPs
Characterization
The size and morphology of In vitro release of PTX from Fe 3 O 4 @GEL MNPs was performed in phosphate buffer saline (PBS) containing 0.5 wt% Tween-80 (0.01 m, pH 7.4) at 37 °C using a dialysis method. One milliliter of this suspension (PTX content, 0.3 mg/mL) was transferred into a dialysis bag (MWCO = 12-14 kDa) and then immersed into 14 mL fresh medium at 37 °C. The samples were placed in an orbital shaker bath, which was maintained at 37 °C and horizontally shaken at 100 rpm. At predetermined time intervals, 14 mL of the released medium was withdrawn, filtered (pore size = 0.20 μm), and replaced with an equal amount of fresh medium. As shown in Figure 3a DLE is an important property in drug-loaded nanocarriers and directly affects the therapeutic effect of the system. The higher encapsulation capacity NPs have, the larger number of drug are released at the tumor site. In this study, the DLE of Fe 3 O 4 @GEL was found to be 86.7 ± 3.2 %. The result demonstrated that Fe 3 O 4 @GEL with the high DLE have the potential to be delivered more efficiently to tumor tissues. In vitro release profiles of free PTX and PTX from PTX-loaded Fe 3 O 4 @GEL were performed in order to evaluate the stability and release behavior of Fe 3 O 4 @GEL. As shown in Figure 3c , the prepared Fe 3 O 4 @GEL showed a long term stable drug release profile up to 5 days. The cumulative release amount of PTX in the initial 3 h was around 10 % as compared with 34% of free PTX. The initial release of PTX could be explained by the PTX molecules, which were absorbed into the outer GEL layer of 
CONCLUSION
In this study, GEL have been successfully coated on Fe 3 O 4 NPs with 10 nm in size and high saturation magnetization. The PTX-loaded Fe 3 O 4 @GEL showed a steady and sustained release profile in vitro up to 5 days. These results suggest that the PTX-loaded Fe 3 O 4 @GEL NPs may serve as stable delivery systems with dual therapeutic effects (hyperthermia combined with chemotherapy) for cancer therapy.
